Hepatocellular carcinoma
Conditions
Interventions
Control group:Receiving conventional therapy
Experimental Group:Receiving TACE + bevacizumab arterial perfusion
Sponsors
The First Hospital of Hebei Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: 1.Age: 18 to 70 years old, gender not limited. 2. Diagnosed with hepatocellular carcinoma, with evidence of cancer cell invasion in the portal vein; 3. Liver function is well preserved, with A Child-Pugh score of A or B; 4. No severe dysfunction of the heart, kidneys or other vital organs; 5. There are complete clinical data and follow-up data; Sign informed consent for the plan.
Exclusion criteria
Exclusion criteria: 1. Have a history of treatment for other types of cancer or other malignant tumors within the past five years; 2. Patients who have received liver transplants or are planning to undergo liver transplants; 3. There are serious complications, such as heart disease, decompensated liver cirrhosis, active bleeding, etc. 4. Pregnant or lactating women; 5. Patients with known severe allergic reactions to the investigational drug (bevacizumab).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Size and number of tumors ; | — |
Secondary
| Measure | Time frame |
|---|---|
| VEGF levels ;Tumor vascular density;Incidence of adverse reactions;Overall survival;PDGF level; | — |
Countries
China
Contacts
Public ContactBingzheng Yan
The First Hospital of Hebei Medical University
Outcome results
None listed